VantAI, an AI firm specializing in programmable protein interactions, has entered a $1 billion+ partnership with clinical-stage biotech Halda Therapeutics. The collaboration leverages VantAI's Neo-1 structural proteomics platform and NeoLink data to discover novel target-effector protein pairs critical for Halda’s Regulated Induced Proximity Targeting Chimeras (RIPTACs) pipeline, aiming to create selective therapies for cancer and immune diseases. This alliance reflects increased industry focus on AI-enabled drug discovery and proximity-based modalities to address previously undruggable targets.